Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants.
Kansagra KA, Momin T, Patel HB, Shah C, Parmar G, Ghoghari A, Patel HV, Parmar DV. Kansagra KA, et al. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec 23. doi: 10.1007/s00210-023-02912-9. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 38141084
Global patterns of genomic and phenotypic variation in the invasive harlequin ladybird.
Li H, Peng Y, Wang Y, Summerhays B, Shu X, Vasquez Y, Vansant H, Grenier C, Gonzalez N, Kansagra K, Cartmill R, Sujii ER, Meng L, Zhou X, Lövei GL, Obrycki JJ, Sethuraman A, Li B. Li H, et al. Among authors: kansagra k. BMC Biol. 2023 Jun 19;21(1):141. doi: 10.1186/s12915-023-01638-7. BMC Biol. 2023. PMID: 37337183 Free PMC article.
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat.
Patel H, Momin T, Kansagra K, Patel H, Shah C, Barot A, Bhavsar J, Zala K, Parmar D. Patel H, et al. Among authors: kansagra k. Clin Pharmacol Drug Dev. 2023 Apr;12(4):356-362. doi: 10.1002/cpdd.1206. Epub 2022 Dec 2. Clin Pharmacol Drug Dev. 2023. PMID: 36458679 Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).
Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, Shah C, Patel JM, Ghoghari A, Barot A, Sharma B, Viswanathan K, Patel HV, Jain MR. Parmar DV, et al. Among authors: kansagra ka. Clin Pharmacol Drug Dev. 2023 Feb;12(2):202-211. doi: 10.1002/cpdd.1162. Epub 2022 Sep 5. Clin Pharmacol Drug Dev. 2023. PMID: 36065092 Free PMC article. Clinical Trial.
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).
Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, Ramakrishna C, Bandara Galahitiyawa MC, Mavani SB, Rajanna S, Jikki P, De Silva S, Ruhela V, Koradia P, Kansagra K, Kanani P, Sharma N, Zala K, Parmar D; Study Investigator Group. Agrawal D, et al. Among authors: kansagra k. Am J Nephrol. 2022;53(5):352-360. doi: 10.1159/000523961. Epub 2022 Apr 22. Am J Nephrol. 2022. PMID: 35462372 Free article. Clinical Trial.
40 results